Donanemab TRAILBLAZER-ALZ 2 Trial

Overview

TRAILBLAZER-ALZ 2 (NCT04437511) was a landmark Phase 3 clinical trial evaluating donanemab in early symptomatic [Alzheimer's disease](/diseases/alzheimers-disease) patients with low-to-medium levels of tau pathology. The trial demonstrated significant clinical slowing of disease progression, leading to FDA approval in 2024[@donanemab2023].

Overview

TRAILBLAZER-ALZ 2 (NCT04437511) was a landmark Phase 3 clinical trial evaluating donanemab in early symptomatic [Alzheimer's disease](/diseases/alzheimers-disease) patients with low-to-medium levels of tau pathology. The trial demonstrated significant clinical slowing of disease progression, leading to FDA approval in 2024[@donanemab2023].

Donanemab represents a significant advancement in Alzheimer's disease therapy as the second anti-amyloid antibody to receive FDA approval, following lecanemab. The trial also pioneered the use of tau-based patient selection, which may improve treatment response prediction.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04437511 |
| Phase | Phase 3 |
| Status | Completed |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,736 patients |
| Duration | 18 months (blinded period) |
| Location | Multiple countries (US, Canada, UK, EU, Japan, Australia) |
| Randomization | 1:1 (donanemab:placebo) |

Mechanism of Action

Target: N3pG Amyloid Plaque

Donanemab is a monoclonal antibody that targets a specific form of aggregated amyloid-beta plaque with the N3pG (pyroglutamate) epitope[@donanemab2023]. This epitope is found on mature, dense-core plaques that are most closely associated with Alzheimer's disease pathology.

Binding Specificity:

• Recognizes the N-terminal pyroglutamate-modified Aβ (AβpE3)
• Binds with high affinity to aggregated plaques
• Minimal binding to soluble monomeric Aβ
• Selects for pathologically relevant species

Clearance Mechanism

The antibody facilitates plaque removal through microglial-mediated clearance:

This mechanism differs from earlier anti-Aβ antibodies that targeted soluble Aβ species, potentially explaining the robust plaque clearance observed with donanemab[@mintun2021].

Patient Population

Eligibility Criteria

Inclusion Criteria:
| Criterion | Requirement |
|-----------|--------------|
| Age | 60-85 years |
| Diagnosis | MCI due to AD or mild AD dementia |
| MMSE score | 20-28 |
| Amyloid PET | Positive (centiloid ≥40) |
| Tau PET | Low-to-medium tangles (intermediate tau) |

Tau-Based Enrichment Strategy

The trial employed a novel tau-based stratification approach:

• Low-to-medium tau: Patients with limited tau pathology represent earlier disease stage
• High tau excluded: Patients with advanced tau pathology were enrolled in separate TRAILBLAZER-ALZ 3
• Rationale: Anti-amyloid therapy may be less effective in patients with advanced tau spread

Trial Design

Study Schema

Screening → Randomization (1:1) → 18-Month Treatment → Follow-up
↓ ↓
Donanemab IV q4w Placebo IV q4w

Treatment Regimen

• Dosing: 1,400 mg IV every 4 weeks (after titration)
• Duration: 18 months
• Plaque monitoring: Amyloid PET at 6, 12, and 18 months
• Stopping rule: Discontinue if amyloid cleared before 18 months

Endpoints

Primary Endpoint

iADRS (Integrated Alzheimer's Disease Rating Scale) at 18 months:

• Composite measure combining cognitive and functional domains
• Includes MMSE, ADAS-Cog, and functional assessments
• Sensitive to early-stage AD changes

Secondary Endpoints

| Endpoint | Domain |
|----------|--------|
| CDR-SB | Clinical dementia staging |
| ADAS-Cog13 | Cognitive function |
| ADCS-MCI-ADL | Daily functioning |
| Amyloid PET SUVr | Plaque burden |
| Tau PET | Tau pathology progression |

Results

Primary Efficacy

TRAILBLAZER-ALZ 2 met its primary endpoint with statistically significant results[@sims2023]:

| Measure | Donanemab | Placebo | Treatment Effect |
|---------|-----------|---------|------------------|
| iADRS change | -6.02 | -10.36 | -4.34 (35% slowing, p<0.001) |
| CDR-SB change | -1.72 | -2.42 | 0.70 (29% slowing) |

Clinical Interpretation:

• 35% slowing of clinical decline is meaningful
• Patients gained an additional ~7 months of cognitive benefit
• Effect size comparable to or better than lecanemab

Amyloid Clearance

Plaque Removal:

• 84% of patients achieved amyloid clearance (below threshold) at 12 months
• 90% achieved clearance at 18 months
• Earlier clearance correlated with better clinical outcomes

Adverse Events

| Adverse Event | Donanemab | Placebo |
|---------------|-----------|---------|
| ARIA-E (edema) | 24% | 2% |
| ARIA-H (hemorrhage) | 31% | 13% |
| Infusion reactions | 8% | <1% |
| Discontinuation due to AE | 6% | 2% |

ARIA Management:

• ARIA-E (amyloid-related imaging abnormalities - edema): Brain swelling
• ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis
• Monitored with MRI; most cases mild/asymptomatic
• Higher risk in ApoE ε4 carriers

FDA Approval

Regulatory Decision

In July 2024, the FDA approved donanemab (brand name Kisunly) for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia.

Approval Conditions:

• Indicated for early AD (MCI or mild dementia)
• Requires confirmed amyloid pathology
• Recommended monitoring for ARIA

Comparison with Other Anti-Amyloid Therapies

| Feature | Donanemab | Lecanemab | Aducanumab |
|---------|-----------|------------|------------|
| Target | N3pG-Aβ | Protofibrils | Monomers/oligomers |
| Dosing | q4w IV | q2w IV | q4w IV |
| Plaque clearance | 84-90% | ~60% | ~70% |
| ARIA-E rate | 24% | 13% | 35% |

Clinical Significance

Disease Modification

The 35% slowing of clinical decline represents evidence of disease modification:

Challenges and Limitations

• ARIA risk: Requires careful monitoring, especially in ApoE ε4 carriers
• Limited benefit: Not all patients respond equally
• Treatment window: Benefits early-stage patients most
• Access: IV infusion every 4 weeks is burdensome

Future Directions

TRAILBLAZER-ALZ 3:

• Enrolling patients with high tau pathology
• Will determine if donanemab benefits later-stage AD

• Donanemab + other disease-modifying agents
• Anti-amyloid + anti-tau combinations

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Donanemab (Kisunly)](/therapeutics/donanemab)
• [Amyloid-Targeting Therapies](/therapeutics/amyloid-targeting-therapies)
• [Tau Pathology](/mechanisms/tau-pathography)
• [Amyloid-Related Imaging Abnormalities](/biomarkers/aria)

External Links

• [ClinicalTrials.gov - NCT04437511](https://clinicaltrials.gov/ct2/show/NCT04437511)
• [PubMed - Donanemab JAMA 2023](https://pubmed.ncbi.nlm.nih.gov/37327284/)
• [Eli Lilly Donanemab Information](https://www.lilly.com/)

References